150 related articles for article (PubMed ID: 16866639)
1. Point-of-care diagnostics: will the hurdles be overcome this time?
Huckle D
Expert Rev Med Devices; 2006 Jul; 3(4):421-6. PubMed ID: 16866639
[TBL] [Abstract][Full Text] [Related]
2. Point-of-care diagnostics: an advancing sector with nontechnical issues.
Huckle D
Expert Rev Mol Diagn; 2008 Nov; 8(6):679-88. PubMed ID: 18999920
[TBL] [Abstract][Full Text] [Related]
3. Diagnosing infections--current and anticipated technologies for point-of-care diagnostics and home-based testing.
Bissonnette L; Bergeron MG
Clin Microbiol Infect; 2010 Aug; 16(8):1044-53. PubMed ID: 20670286
[TBL] [Abstract][Full Text] [Related]
4. Point of care diagnostics: status and future.
Gubala V; Harris LF; Ricco AJ; Tan MX; Williams DE
Anal Chem; 2012 Jan; 84(2):487-515. PubMed ID: 22221172
[No Abstract] [Full Text] [Related]
5. Molecular diagnostics: hurdles for clinical implementation.
Fortina P; Surrey S; Kricka LJ
Trends Mol Med; 2002 Jun; 8(6):264-6. PubMed ID: 12067610
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care testing and molecular diagnostics: miniaturization required.
Kiechle FL; Holland CA
Clin Lab Med; 2009 Sep; 29(3):555-60. PubMed ID: 19840687
[TBL] [Abstract][Full Text] [Related]
7. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
8. Emerging technologies in point-of-care molecular diagnostics for resource-limited settings.
Peeling RW; McNerney R
Expert Rev Mol Diagn; 2014 Jun; 14(5):525-34. PubMed ID: 24784765
[TBL] [Abstract][Full Text] [Related]
9. Emerging technologies for point-of-care genetic testing.
Dobson MG; Galvin P; Barton DE
Expert Rev Mol Diagn; 2007 Jul; 7(4):359-70. PubMed ID: 17620045
[TBL] [Abstract][Full Text] [Related]
10. New solutions for personalised health management: citizens' needs, healthcare changes, and market perspectives round table debate.
Olsson S; Hofmann I; Brambilla PM; Jacobsson U; Kennedy P; Roca J; Schmitt KJ; Wyke A
Stud Health Technol Inform; 2004; 108():305-12. PubMed ID: 15718660
[TBL] [Abstract][Full Text] [Related]
11. Translating in vivo diagnostics into clinical reality.
Frangioni JV
Nat Biotechnol; 2006 Aug; 24(8):909-13. PubMed ID: 16900127
[No Abstract] [Full Text] [Related]
12. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
13. Point-of-care molecular diagnostic systems--past, present and future.
Holland CA; Kiechle FL
Curr Opin Microbiol; 2005 Oct; 8(5):504-9. PubMed ID: 16098787
[TBL] [Abstract][Full Text] [Related]
14. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
Walk EE
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a training program for device operators in the Australian Government's Point of Care Testing in General Practice Trial: issues and implications for rural and remote practices.
Shephard MD; Mazzachi BC; Watkinson L; Shephard AK; Laurence C; Gialamas A; Bubner T
Rural Remote Health; 2009; 9(3):1189. PubMed ID: 19689171
[TBL] [Abstract][Full Text] [Related]
16. Physician refer thyself: is Stark II, phase III the final voyage?
Manchikanti L; McMahon EB
Pain Physician; 2007 Nov; 10(6):725-41. PubMed ID: 17987094
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnostics: a historical perspective.
Tsongalis GJ; Silverman LM
Clin Chim Acta; 2006 Jul; 369(2):188-92. PubMed ID: 16701603
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine: elusive dream or imminent reality?
Lesko LJ
Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
[TBL] [Abstract][Full Text] [Related]
20. Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology.
Gibbs JN
Expert Rev Mol Diagn; 2011 May; 11(4):367-81. PubMed ID: 21545255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
